Efficacy and Safety of High-Flow Nasal Cannula Versus Noninvasive Ventilation for Pulmonary Arterial Hypertension-Associated Acute Respiratory Failure

Active, not recruitingOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions
Pulmonary Arterial HypertensionAcute Respiratory FailureHigh-flow Nasal CannulaNoninvasive Ventilation
Interventions
DEVICE

HFNC treatment

HFNC treatment HFNC therapy. The initial flow rate of 50-60 L/min was subsequently adjusted to maintain an oxygen saturation (SpO2) ≥92%. The FiO2 was titrated to maintain the PaO2 between 60 and 80 mmHg.

DEVICE

NIV treatment

NIV treatment A Mindray SV300 ventilator (Mindray Medical International Limited, Shenzhen, China) was used to deliver NIV via an oronasal mask. The initial inspiratory positive airway pressure (IPAP) was 12-15 cmH2O and adjusted later to achieve a tidal volume of 6-8 mL/kg of predicted body weight and a respiratory rate of \<30 breaths/min. The expiratory positive airway pressure (EPAP) was established at 5-8 cmH2O. Additional-ly, FiO2 was titrated to maintain a PaO2 between 60 and 80 mmHg.

Trial Locations (1)

641000

The First People's Hospital of Neijiang City, Neijiang

All Listed Sponsors
lead

The First People's Hospital of Neijiang

OTHER